share_log

Transcode Therapeutics | DEFA14A: Others

SEC announcement ·  Jun 10 20:48
Summary by Futu AI
TransCode Therapeutics, Inc., an RNA oncology company, has announced that it has regained compliance with Nasdaq's listing standards, ensuring that its stock will continue to be listed and traded on the Nasdaq Stock Market. The scheduled Nasdaq Hearing Panel on June 25, 2024, has been cancelled as a result of this compliance. The company is under Nasdaq panel monitoring until January 26, 2025. This news follows recent positive developments, including promising blood test results from a Phase 0 clinical trial and FDA authorization for a Phase 1 study. Interim CEO and CFO Tom Fitzgerald expressed confidence in the company's trajectory and noted that a reverse stock split is not anticipated due to the share price exceeding the $1.00 minimum bid price required by Nasdaq. TransCode focuses on developing RNA therapeutics for metastatic cancer, with its lead candidate, TTX-MC138, targeting tumors that overexpress microRNA-10b. The company's proprietary TTX nanoparticle platform is central to its strategy for delivering RNA-based treatments.
TransCode Therapeutics, Inc., an RNA oncology company, has announced that it has regained compliance with Nasdaq's listing standards, ensuring that its stock will continue to be listed and traded on the Nasdaq Stock Market. The scheduled Nasdaq Hearing Panel on June 25, 2024, has been cancelled as a result of this compliance. The company is under Nasdaq panel monitoring until January 26, 2025. This news follows recent positive developments, including promising blood test results from a Phase 0 clinical trial and FDA authorization for a Phase 1 study. Interim CEO and CFO Tom Fitzgerald expressed confidence in the company's trajectory and noted that a reverse stock split is not anticipated due to the share price exceeding the $1.00 minimum bid price required by Nasdaq. TransCode focuses on developing RNA therapeutics for metastatic cancer, with its lead candidate, TTX-MC138, targeting tumors that overexpress microRNA-10b. The company's proprietary TTX nanoparticle platform is central to its strategy for delivering RNA-based treatments.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.